Osteopore Limited designs, develops, and markets bioresorbable polymer implants for neurosurgical, orthopedic, and maxillofacial surgery applications.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.28|
|52 Week High||AU$0.26|
|52 Week Low||AU$0.65|
|1 Month Change||-8.33%|
|3 Month Change||-27.63%|
|1 Year Change||-46.08%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-62.07%|
Recent News & Updates
|OSX||AU Medical Equipment||AU Market|
Return vs Industry: OSX underperformed the Australian Medical Equipment industry which returned -7.6% over the past year.
Return vs Market: OSX underperformed the Australian Market which returned 21.3% over the past year.
Stable Share Price: OSX is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: OSX's weekly volatility (10%) has been stable over the past year.
About the Company
|2003||n/a||Khoon Seng Goh||https://www.osteopore.com|
Osteopore Limited designs, develops, and markets bioresorbable polymer implants for neurosurgical, orthopedic, and maxillofacial surgery applications. It specializes in the production of 3D printed bioresorbable implants that are used in conjunction with surgical procedures to assist with the natural stages of bone healing. The company offers Osteoplug, a bioresorbable implant, which is used for covering trephination burr holes in neurosurgery; Osteomesh, a bioresorbable implant that is used in craniofacial surgery to repair various types of fractures, such as orbital floor fracture, as well as to fill surgical defects; and Osteostrip.
Osteopore Fundamentals Summary
|OSX fundamental statistics|
Is OSX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|OSX income statement (TTM)|
|Cost of Revenue||AU$486.34k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.022|
|Net Profit Margin||-181.43%|
How did OSX perform over the long term?See historical performance and comparison
Is Osteopore undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate OSX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate OSX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: OSX is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.
PE vs Market: OSX is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OSX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OSX is good value based on its PB Ratio (4.2x) compared to the AU Medical Equipment industry average (4.5x).
How is Osteopore forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Osteopore has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Osteopore performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OSX is currently unprofitable.
Growing Profit Margin: OSX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OSX is unprofitable, and losses have increased over the past 5 years at a rate of 25% per year.
Accelerating Growth: Unable to compare OSX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OSX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).
Return on Equity
High ROE: OSX has a negative Return on Equity (-34.62%), as it is currently unprofitable.
How is Osteopore's financial position?
Financial Position Analysis
Short Term Liabilities: OSX's short term assets (A$8.2M) exceed its short term liabilities (A$1.1M).
Long Term Liabilities: OSX has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: OSX's debt to equity ratio (4.1%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if OSX's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OSX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: OSX has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 38.3% each year.
What is Osteopore current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OSX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OSX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OSX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OSX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OSX's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Khoon Seng Goh
Mr. Khoon Seng Goh is the Chief Executive Officer of Osteopore Limited (formerly, Osteopore International Pte. Ltd.) since September 23, 2019 and had been its Director since December 11, 2018 until June 24...
CEO Compensation Analysis
Compensation vs Market: Khoon Seng's total compensation ($USD162.50K) is below average for companies of similar size in the Australian market ($USD302.38K).
Compensation vs Earnings: Khoon Seng's compensation has been consistent with company performance over the past year.
Experienced Management: OSX's management team is considered experienced (2.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Osteopore Limited's employee growth, exchange listings and data sources
- Name: Osteopore Limited
- Ticker: OSX
- Exchange: ASX
- Founded: 2003
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: AU$32.249m
- Shares outstanding: 117.27m
- Website: https://www.osteopore.com
- Osteopore Limited
- No. 09-06, 2 Tukang Innovation Grove
- MedTech Hub
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/25 16:54|
|End of Day Share Price||2021/10/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.